The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2016
At a glance
- Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms LUMEN
- 04 Apr 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov.
- 04 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov.
- 07 May 2013 New trial record